Evaluation of HIF-1 inhibitors as anticancer agents
- 31 October 2007
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 12 (19-20), 853-859
- https://doi.org/10.1016/j.drudis.2007.08.006
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Metastasis and stem cell pathwaysCancer and Metastasis Reviews, 2007
- Hypoxia, gene expression, and metastasisCancer and Metastasis Reviews, 2007
- HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional ActivityCancer Cell, 2007
- RACK1 Competes with HSP90 for Binding to HIF-1α and Is Required for O2-Independent and HSP90 Inhibitor-Induced Degradation of HIF-1αMolecular Cell, 2007
- Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1α C-Terminal Activation DomainMolecular and Cellular Biology, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- Expression of hypoxia-inducible factor (HIF)-1α is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinomaEuropean Journal Of Cancer, 2004
- Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1α (HIF-1α): structural requirement of bisphenol A for degradation of HIF-1αBiochemical and Biophysical Research Communications, 2004
- GL331 inhibits HIF-1α expression in a lung cancer modelBiochemical and Biophysical Research Communications, 2003
- Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activityBiochemical and Biophysical Research Communications, 2002